Validación del índice de gravedad del síndrome de Cushing en pacientes con síndrome de Cushing iatrógénico

González-Albarrán, 2000, Síndrome de Cushing, Medicine, 8, 1102 Czok, 2005, Pharmacokinetics and pharmacodynamics of systemically administeral glucocorticoids, Clin Pharmacokinet, 44, 61, 10.2165/00003088-200544010-00003 Axelrod, 1976, Glucocorticoid therapy, Medicine, 56, 39, 10.1097/00005792-197601000-00003 Sonino, 2000, A clinical index for rating severity in Cushing's síndrome, Psychother Psychosom, 69, 216, 10.1159/000012396 Buttgereit, 2002, Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology, Ann Rheum Dis, 61, 718, 10.1136/ard.61.8.718 Muller, 1987, Body circunferences as alternatives to skinfold measuraments of body fat distribution in Mexican-Americans, Int J Obes, 11, 309 Wallace, 1951, The exposure of burns, Lancet., i, 501, 10.1016/S0140-6736(51)91975-7 Curtis, 2006, Population-based assessment of adverse events associated with long-term glucocorticoid use, Arthritis Care Res, 55, 420, 10.1002/art.21984 Leung, 2003, Update on glucocorticoid action and resistance, J Allergy Clin Immunol., 111, 3, 10.1067/mai.2003.97 Pujols, 2004, Glucocorticoid receptors in human airways, Allergy, 59, 1042, 10.1111/j.1398-9995.2004.00635.x Boumpas, 1996, A novel action of glucocorticoids –NF-kB inhibition, Br J Rheumatol, 35, 709, 10.1093/rheumatology/35.8.709